Elizabeth McFarland, MD

For Patients:
Dr. McFarland’s primary areas of research interest are HIV passive and active immunization and immune-based HIV therapy, the role of HIV-specific cell-mediated immunity in HIV pathogenesis and response to therapy and RSV vaccine clinical trials. She is leading clinical research protocols focused on HIV-1 specific broadly neutralizing monoclonal antibody (bNAb) for infants exposed to HIV-1 and for infant early antiretroviral treatment. She serves as Vice Chair of the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) HIV Cure Committee, as member of the Pediatric Advisory Committee to the HIV Vaccine Trials Network (HVTN), as a co-investigator for the Pediatrics Adolescent Virus Eradication (PAVE) Martin Delaney Collaboratory, site principal investigator for the multicenter Pediatric AIDS/HIV Cohort Study (PHACS), and member of the PHACS Nutrition, Metabolic, Growth Working Group. She has served on the AIDS Research Advisory Council, Division of AIDS (DIADS) at the National Institutes of Health (NIH). Dr. McFarland has had continuous NIH and HRSA funding since 1995.

For Referring Providers:
Dr. McFarland’s primary areas of research interest are HIV passive and active immunization and immune-based HIV therapy, the role of HIV-specific cell-mediated immunity in HIV pathogenesis and response to therapy and RSV vaccine clinical trials. She is leading clinical research protocols focused on HIV-1 specific broadly neutralizing monoclonal antibody (bNAb) for infants exposed to HIV-1 and for infant early antiretroviral treatment. She serves as Vice Chair of the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) HIV Cure Committee, as member of the Pediatric Advisory Committee to the HIV Vaccine Trials Network (HVTN), as a co-investigator for the Pediatrics Adolescent Virus Eradication (PAVE) Martin Delaney Collaboratory, site principal investigator for the multicenter Pediatric AIDS/HIV Cohort Study (PHACS), and member of the PHACS Nutrition, Metabolic, Growth Working Group. She has served on the AIDS Research Advisory Council, Division of AIDS (DIADS) at the National Institutes of Health (NIH). Dr. McFarland has had continuous NIH and HRSA funding since 1995.